Mind Medicine, Inc., a neuro-pharmaceutical company, discovers, develops, and deploys psychedelic inspired medicines to improve health and wellness, and alleviate suffering.
The last earnings update was 9 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Mind Medicine (MindMed). This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Mind Medicine (MindMed)'s
is considered below, and whether this is a fair price.
Price based on past earnings
Mind Medicine (MindMed)'s earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mind Medicine (MindMed) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Mind Medicine (MindMed)
expected to grow at an
Unable to compare Mind Medicine (MindMed)'s earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Mind Medicine (MindMed)'s earnings growth to the Germany market average as no estimate data is available.
Unable to compare Mind Medicine (MindMed)'s revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Mind Medicine (MindMed) is high growth as no earnings estimate data is available.
Unable to determine if Mind Medicine (MindMed) is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Mind Medicine (MindMed)'s performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Mind Medicine (MindMed)
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Mind Medicine (MindMed)'s finances.
The net worth of a company is the difference between its assets and liabilities.
Mind Medicine (MindMed) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Mind Medicine (MindMed) has no long term commitments.
This treemap shows a more detailed breakdown of
Mind Medicine (MindMed)'s finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Mind Medicine (MindMed) has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Stephen L. Hurst, also known as Steve, J.D. serves as Executive Chair, Co-Chief Executive Officer and Secretary at Mind Medicine (MindMed) Inc. since February 2020. Mr. Hurst has been Chief Business Officer of The Immune Tolerance Institute June 2007. Mr. Hurst served as Vice President of Human Resources of Nektar Therapeutics since July 2001. Mr. Hurst served as Vice President, General Counsel and Secretary from August 1998 to July 2001 and as Vice President, Intellectual Property and Licensing from March 1994 to August 1998. Mr. Hurst was in private law practice and consulted with COR Therapeutics, Inc., a biotechnology company, on intellectual property and business development issues from July 1990 to February 1994. He served as Campus Patent Coordinator for the University of California, San Francisco from November 1987 to June 1990. He also worked as an Associate Counsel at Townsend & Townsend, a San Francisco based law firm. Mr. Hurst has more than years’ experience in the biopharmaceutical industry. Prior to co-founding MindMed PrivateCo, he was cofounder and CEO of Savant HWP, Inc. (2009-2019). He served as Senior Vice President of Operations and General Counsel at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.) (1994-2002). He has also served as a consultant to The World Bank and BIO Ventures for Global Health (2005-2009), advancing the PneumoAMC program. He received a B.S degree in Environmental Science from the University of California at Berkeley and his J.D from Golden Gate University in San Francisco.
Insufficient data for Steve to compare compensation growth.
Insufficient data for Steve to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure of the
Mind Medicine (MindMed)
management team in years:
The average tenure for the Mind Medicine (MindMed) management team is less than 2 years, this suggests a new team.
President & Chief Medical Officer
Interim Chief Financial Officer
Chief Operating Officer
Chief Scientific Officer
Board of Directors Tenure
Average tenure and age of the
Mind Medicine (MindMed)
board of directors in years:
The average tenure for the Mind Medicine (MindMed) board of directors is less than 3 years, this suggests a new board.
Board of Directors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Mind Medicine, Inc., a neuro-pharmaceutical company, discovers, develops, and deploys psychedelic inspired medicines to improve health and wellness, and alleviate suffering. The company focuses on the development of 18-methoxycoronaridine, an alpha-3-beta-4 nicotinic receptor antagonist that modulates excessive dopamine fluctuations in the mesolimbic system of the brain for treating various forms of addiction. It is also involved in the Phase II clinical trials of LSD microdosing for adult ADHD. The company is headquartered in Reno, Nevada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.